Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2023; 29(44): 5907-5918
Published online Nov 28, 2023. doi: 10.3748/wjg.v29.i44.5907
Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study
Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng, Lei Fu
Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng, Lei Fu, Department of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China
Author contributions: Fu L designed the research and supervised the study; Peng WT, Chen KY, Zhou NQ, and Yang FL collected the clinical data; Peng WT, Liu JQ, and Jiang C performed the experiments and wrote the manuscript; Peng SF assisted in experiments; all authors critically reviewed the final manuscript.
Supported by National Natural Science Foundation of China, No. 82170640, and No. 81974080; Natural Science Foundation of Hunan Province, No. 2022JJ30954.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Xiangya Hospital Central South University.
Informed consent statement: The study is a retrospective study that will maximize the protection of the rights and privacy of the study participants, and the content of the study and the results of the study do not involve personal privacy and commercial interests, exempt from informed consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Fu, MD, PhD, Professor, Department of Infectious Diseases, Xiangya Hospital Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. fulei92@126.com
Received: September 2, 2023
Peer-review started: September 2, 2023
First decision: October 16, 2023
Revised: October 29, 2023
Accepted: November 14, 2023
Article in press: November 14, 2023
Published online: November 28, 2023
Processing time: 86 Days and 2.3 Hours
Core Tip

Core Tip: This is a retrospective study to compare the efficacy and safety of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) for 48 wk in patients with chronic hepatitis B (CHB). Our study found that TMF is as effective as TAF in treating CHB and has comparable safety profiles. In addition, TAF may cause deterioration of lipid profiles. These results suggest that TMF may be a viable alternative to TAF for CHB treatment.